PDF
ePub
Citation
Print
INTRODUCTION
Depression is a highly prevalent mental disease that is prone to recurrence and chronicity, and the WHO forecasted that this disease would be second only to heart disease as a cause of loss of healthy years by 2020 (1). Nevertheless, due to its pathological features, the treatment of depression has not been systematized, but is dependent on the experience of individual pathologists. As an attempt to overcome such circumstances, ceaseless efforts have been made worldwide for the development of an evidence-based clinical practice guideline that would suggest therapeutic recommendations systematically (2).
The treatment guideline development team judged that the Republic of Korea currently has, at least, the minimum infrastructure needed for producing an evidence-based clinical practice guideline. This decision was based on the improved national environment, in which rapidly growing information and communication networks now provide up-to-date knowledge on treatment, which can be accessed and applied efficiently. In 2005, the Republic of Korea Government began to take note of the seriousness of major depressive disorder (MDD) and realized that a guideline would be essential for the improved and systematic treatment of depression, and at last decided to build a national depression clinical research center as a national health and medical treatment technology infrastructure development project. Our research team developed the "Evidence-based, Pharmacological Treatment Guideline for Depression in Korea" in 2008 (3), and developed the "Evidence-based, Non-pharmacological Treatment Guideline for Depression in Korea" in 2010 (4). Due to the limitations of the initial pharmacological treatment guideline, the accumulation of new clinical information with time, and the emphasis on the importance of a guideline reflecting the current local clinical situation, the "Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition" was released in 2012 (5). In an attempt to inform Korean practitioners of the recommendations made in the revised edition, papers reporting certain recommendations of the guideline were published in the Korean language (6, 7, 8). However, an introduction to the guideline as a whole has not yet been made, and no report on the guideline has ever been written in English. Therefore, the existence of a Korean evidence-based, pharmacological treatment guideline for depression has not yet been acknowledged outside Korea. To provide a broad introduction and wide distribution of this guideline, a summary of the guideline written in English has been greatly needed. Hence, the aim of this article is to introduce, summarize, and emphasize the importance of the "Evidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition".
HOW THE GUIDELINES WERE PREPARED
Clinical practice guideline development group composition
The clinical practice guideline development group was composed of a multidisciplinary team from the Clinical Research Center for Depression, in order to expand their network to include psychiatrists, research administrators, clinical psychologists, and experts on systematic reviews, preventive medicine, and methodology. From key question selection to recommendation development the group members conducted comparative assessments of all the results at every phase while conducting the education or practice necessary for each phase, in an attempt to determine the scientific methods necessary for developing this evidence-based treatment guideline.
Key question development
A treatment guideline is prepared by following a standard procedure that includes selecting clinical questions that need to be answered for the diagnosis and treatment of a specific disease or health problem, and by collecting and classifying this information and preparing the recommendations for the corresponding questions. Therefore, defining these key questions is the first step of collecting and evaluating evidence. This step is important, as it is the basis of the scientific evidence chosen to comprise the guideline. The key questions for this revised guideline were chosen from key questions that typically arise from the beginning until the end of the pharmacological treatment of a patient diagnosed with moderate to severe MDD according to the DSM-IV TR. In order for the questions to be answered accurately and correctly, the "PICO" method was used. The questions include the following four elements. P (patient population) represents patients or corresponding problems; I (intervention) represents the main intervention activities such as diagnostic procedures, prognostic factors, and treatment; C (comparison) represents comparative intervention; and O (outcome) represents the clinical result (9). The key questions broadly cover most aspects of the pharmacological treatment of MDD patients, such as the initiation of antidepressant treatment, efficacy and side effects of treatment, increase in drug dosage, and augmentation, combination, and switching of medication.
Adaptation process
The clinical practice guideline adaptation manual (version 1.0) (10), which was originally developed by the ADAPTE Collaboration, translated under the official approval of the original Bureau of Clinical Research Support Center, and modified to fit the current clinical environment of Korea, was used for the adaptation and revision of this new guideline. The guideline went through most of the processes proposed in the modified manual.
Search of treatment guidelines
A comprehensive search of the National Guideline Clearing-house, NHS Evidence, Guidelines International Network, and PubMed was conducted. 2,526 articles were identified, and among them, only the guidelines prepared by governments, states, or learned societies were selected from the search list. Based on these inclusion criteria, 21 depression treatment guidelines were selected.
Evaluation of treatment guidelines
The 21 studies on treatment guidelines for depression were selected and evaluated by a working group composed of a psychiatrist, a specialist on preventive medicine, and a clinical psychologist, using the AGREE II Tool. The selected studies were assessed for all of the 6 domains of AGREE II, that is, the scope and purpose, stakeholder involvement, rigor of development, clarity of presentation, applicability, and editorial independence. The total score was converted to a percentile, and depending on the converted scores, weighted values were assigned as follows: 3 points for a score 60 and above, 2 points for 40 and above but less than 60, 1 point for a score below 40. The points were then summed (with the total of 18 points). Among the studies, 12 articles were found to be of good quality and were finally selected as shown in Table 1. The consistency of the evidence itself, the interpretation of evidence, and the recommendations in each treatment guideline were reviewed. The scientific feasibility of the treatment guidelines was also reviewed and integrated by examining the validity, the standard level and the consistency of the evidence, and the concordance with other treatment guidelines.
Recommendation grades
Expert panel meetings were held for the selection of recommendation statements. A total of 12 experts participated in the evaluation, scoring each statement on a scale of 1 to 9 (1, most inappropriate and 9, most appropriate). Panel meetings were held face to face after preliminary evaluation, results and problems were reviewed and the recommendations were amended, with a second evaluation taking place (11).
Treatment guideline preparation
Once the content of the adapted treatment guideline was decided upon, all past processes were recorded in the guideline draft in detail. The main principles of the drafting process are as follows: The process is transparent and accurate, the content of reference studies is reflected accurately and the studies are appropriately referenced, and it is acknowledged that the original treatment guideline developers have made great contribution. This guideline was prepared based on these principles.
External expert review and approval
The guideline draft was reviewed by five experts (peer review), and the results of the reviews were also reflected in this guideline. A public hearing was held to collect the stakeholders' opinions. Finally the approval of the Korean Neuropsychiatric Association was obtained on April 13, 2011.
KEY QUESTIONS AND RECOMMENDATIONS
Key question 1. What is the first-line treatment agent among antidepressants?
Evidence
In order to be considered a first-line antidepressant, the antidepressant must have the same efficacy as tricyclic antidepressants (TCAs), a favorable tolerance level, and a high safety level even when taken in large doses. As there is sufficient evidence that selective serotonin reuptake inhibitors (SSRIs) satisfy these qualifications, the New Zealand guidelines group, National Institute for Health and Clinical Excellence (NICE), British Association for Psychopharmacology (BAP), and the Clinical Research Center for Depression guidelines have strongly recommended SSRIs as a first-line treatment agent (3, 12, 13, 14). Furthermore, the Canadian Network for Mood and Anxiety Treatments (CANMAT), American Psychiatric Association (APA), and Northern Sydney Central Coast Mental Health Drug & Alcohol (NSCCMHDA) and University of Sydney CADE Clinic guidelines have recommended serotonin and norepinephrine reuptake inhibitors (SNRIs), norepinephrine and dopamine reuptake inhibitors (NDRIs) and norepinephrine and specific serotonergic antidepressants (NaSSAs) as first-line antidepressants (15, 16, 17). TCAs are as effective as SSRIs; however, TCAs have many adverse effects, poor tolerability, and high discontinuation rates. Therefore, TCAs are not recommended as first-line treatment agents (18, 19, 20). However, patients with melancholic depression or patients who have responded well to TCAs previously are recommended to use TCAs as first-line treatment agents.
Key question 2. Is there a difference in tolerability among antidepressants?
Evidence
The APA guideline described SSRIs as superior in their safety profile and tolerability (16). The BAP and World Federation of Societies of Biological Psychiatry (WFSBP) guidelines described SSRIs as having better tolerability than TCAs, and having a lower discontinuation rate (13, 21, 22, 23). In addition, the New Zealand guidelines group reviewed 13 studies on the effects of antidepressants and concluded that SSRIs were superior in tolerability to other antidepressants such as TCAs and venlafaxine (14).
Key question 3. What factors influence the choice of antidepressant medication?
Evidence
The NICE, CANMAT, BAP, Hong Kong, ACP, NSCCMHDA and University of Sydney CADE Clinic, and WFSBP guidelines have recommended considering the potential side effects of the medication and previous history of side effects when on that medication (12, 13, 15, 17, 21, 24, 25). The APA, BAP, Hong Kong, ACP, and WFSBP guidelines have recommended considering the preference of and acceptability to the patient (13, 16, 21, 24, 25). The CANMAT, APA, Hong Kong, ACP, and WFSBP guidelines have also recommended considering the cost of treatment (16, 17, 21, 24, 25). Furthermore, the CANMAT guideline has also recommended considering the age, sex, severity of the illness, availability of medication, and discontinuation symptoms (17), while the BAP, NSCCMHDA and University of Sydney CADE Clinic, and WFSBP guidelines have recommended considering adherence to medication and family history of medication (13, 15, 21). Finally, the WFSBP guideline has also recommended considering the physician's experience with a given drug (15, 21).
Recommendations
It is strongly recommended that the potential side effects of the medication, patient history of having side effects when taking medication, drug interaction, previous treatment response, preference of and acceptability to the patient, cost of treatment, and co-existing diseases all be considered when selecting antidepressants.
Key question 4-1. Which antidepressant is most efficacious in the treatment of atypical depression?
Evidence
The New Zealand guidelines group recommended SSRIs for the treatment of atypical depression, and the NICE, APA, BAP, and NSCCMHDA and University of Sydney CADE Clinic guidelines recommended SSRIs and monoamine oxidase inhibitors (MAOIs) for the treatment of atypical depression (12, 13, 14, 15, 16). Moreover, the APA guideline recommended both MAOIs and SSRIs for the treatment of atypical depression (16); however, MAOIs may be unsuitable due to restrictions on intake of food while on medication.
Key question 4-2. Which antidepressant is most efficacious in the treatment of psychotic depression?
Evidence
The NICE, CANMAT, APA, BAP, NSCCMHDA and University of Sydney CADE Clinic, Texas Department of Mental Health and Mental Retardation (TDMHMR) in collaboration with Texas universities, WFSBP, Clinical Research Center for Depression, and the Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have recommended the augmentation treatment of both antidepressants and antipsychotics rather than antidepressant monotherapy (3, 12, 13, 15, 16, 21, 25, 26, 27).
Key question 4-3. Which antidepressant is most efficacious in the treatment of seasonal depression?
Evidence
The NICE, CANMAT, APA, and BAP guidelines noted that taking bupropion may prevent major depressive episodes in the winter (12, 13, 16, 17). The BAP and WFSBP guidelines have recommended sertraline (28) and fluoxetine (29) for the treatment of seasonal depression (13, 21). The NICE guideline maintained that evidence on antidepressants being effective in treating seasonal depression is insufficient; however, the evidence supports that antidepressants are effective in preventing depression (12). The WFSBP guideline described SSRIs as having efficacy in treating seasonal depression; however, SSRIs take longer to treat symptoms than light therapy and have more side effects (13, 29, 30).
Key question 5-1. Are TCAs more efficacious than placebo in the treatment of depression?
Evidence
The New Zealand guidelines group, NICE, APA, BAP, Hong Kong, WFSBP, Clinical Research Center for Depression, and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have all described TCAs to be superior to placebo in treating depression (3, 12, 13, 14, 16, 24, 27). However, the NICE guideline described TCAs as having more side effects than placebo and a higher discontinuation rate due to the side effects (12).
Key question 5-2. Are MAOIs more efficacious than placebo in the treatment of depression?
Evidence
The NICE and APA guidelines have described moclobemide as more efficacious than placebo (12, 16). The NICE guideline reported that an HRSD score improvement of over 50% was superior to placebo (12). The APA guideline reported that 6 mg per day of transdermal selegiline for 6 weeks was shown to be more efficacious in 177 MDD patients compared to placebo (16, 31, 32, 33). The NICE guideline noted that evidence of tolerability is not sufficient (12).
Key question 5-3. Are SSRIs (including escitalopram) more efficacious than placebo in the treatment of depression?
Evidence
The New Zealand guidelines group, NICE, APA, BAP, Hong Kong, WFSBP, and Clinical Research Center for Depression guidelines have all described SSRIs to be superior to placebo in treating depression (12, 13, 14, 16, 21, 24). In particular, the NICE guideline described SSRIs as having greater efficacy than placebo with HDRS improvement of more than 50%, with similar effects in moderate, severe, and extremely severe depression (12). The BAP guidelines described SSRIs as having a 61% response rate, whereas placebos had a 50% response rate (13). The WFSBP guideline also suggested as evidence, double-blind studies reporting SSRIs as being more efficacious than placebos (34, 35). However, the NICE guideline described the difference in remission rate to be non-significant, and although a significant difference was shown in moderate and extremely severe depression, the effect was not clinically relevant (12).
Key question 5-4. Are SNRIs (venlafaxine, duloxetine) more efficacious than placebo in the treatment of depression?
Evidence
The NICE and APA guidelines have described duloxetine and venlafaxine as being more efficacious than placebo (12, 16). Three studies that compared the efficacy of duloxetine and placebo reported duloxetine to be superior, and the effect size was also statistically superior. At the end of treatment, duloxetine seemed to be efficacious in the improvement of HDRS compared to placebo. However, pain associated with depression showed no significant difference. The discontinuation rate at the early stages of treatment was twice as high for duloxetine compared to placebo, but the discontinuation due to ineffectiveness was twice as high for placebo.
Key question 5-5. Are NaSSAs (mirtazapine) more efficacious than placebo in the treatment of depression?
Evidence
The APA and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have described mirtazapine as having superior efficacy compared to placebo (16, 27). A meta-analysis comparing 6 studies reported that when mirtazapine was taken for 6-8 weeks, superior treatment efficacy was observed compared to placebo (36). Furthermore, the Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guideline identified mirtazapine as having superior antidepressant effects compared to placebo, based on many double-blind studies and meta-analyses (level 1) (27).
Key question 5-6. Are NDRIs (bupropion) more efficacious than placebo in the treatment of depression?
Evidence
The APA and the Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines reported bupropion to be more efficacious than placebo (16, 27). Bupropion showed superior efficacy in the treatment of depression in the acute phase compared to placebo (37), and all three forms of bupropion are more efficacious than placebo (38). In addition, the Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guideline found bupropion to be more efficacious than placebo, based on many double-blind studies (level I) (27).
Key question 5-7. Are serotonin antagonist and reuptake inhibitors (SARIs, trazodone) more efficacious than placebo in the treatment of depression?
Evidence
The APA and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines described trazodone as having a superior antidepressant effect over placebo (16, 27). Trazodone is still widely used, and shows better antidepressant effects compared to placebo (36, 39). Therefore, trazodone is recommended as more efficacious than placebo.
Key question 6-1. When compared to other antidepressants, do TCAs have a different antidepressant efficacy?
Evidence
The NICE, APA, and BAP guidelines have described amitriptyline to be equal or slightly more effective than other antidepressants (SSRIs, SNRIs, MAOIs) (12, 13, 16). Especially in the case of inpatients, amitriptyline showed a slightly higher efficacy than other TCAs or SSRIs (20, 40, 41). In addition, in melancholic depression and severe depression, its efficacy was superior to SSRIs (20). However, many side effects have been reported, and treatment can also be terminated due to the side effects.
Key question 6-2. When compared to other antidepressants, do MAOIs have a different antidepressive efficacy?
Evidence
The NICE, APA, BAP, Hong Kong, NSCCMHDA and University of Sydney CADE Clinic, TDMHMR in collaboration with Texas universities, and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have described MAOIs as having antidepressant efficacy equal to that of other antidepressants (12, 13, 15, 16, 24, 26). A meta-analysis on 12 reversible inhibitor of MAOA studies reported that moclobemide did not show a difference in efficacy compared to imipramine and clomipramine in admitted patients with severe depression or psychotic depression (42).
Key question 6-3. When compared to other antidepressants, do SSRIs have a different antidepressive efficacy?
Evidence
The New Zealand guidelines group, NICE, CANMAT, APA, Hong Kong, and ACP guidelines described SSRIs as having similar antidepressant effects to other agents but better tolerability (12, 14, 16, 17, 24, 25). More than ten meta-analyses have reported SSRIs to be as effective as TCAs (18, 20, 43, 44, 45), and many studies have reported that there is not much evidence that other antidepressants are more effective than SSRIs (43, 46, 47, 48, 49, 50). Furthermore, the New Zealand guidelines group reported that escitalopram is superior to other SSRIs and venlafaxine (14, 49). SSRIs are also relatively safe when taken in large amounts, so they are recommended as a first-line treatment and also to patients with a risk of suicide. However, some studies have reported that SNRIs are superior to SSRIs in the remission of symptoms (51).
Key question 6-4. When compared to other antidepressants, do SNRIs have a different antidepressive efficacy?
Evidence
The NICE, CANMAT, APA, BAP, WFSBP, NSCCMHDA and University of Sydney CADE Clinic, Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology, and the Clinical Research Center for Depression guidelines have described venlafaxine and duloxetine to be equal or better in efficacy compared to other antidepressants (3, 12, 13, 15, 16, 17, 21, 27). The CANMAT guideline described venlafaxine to be superior to duloxetine, fluoxetine, and pooled SSRIs, and duloxetine to be superior to paroxetine and pooled SSRIs (17). The APA guideline reported venlafaxine and duloxetine to be as effective as SSRIs (16, 52, 53). A few studies have recommended SNRIs as more beneficial than SSRIs (51). However, there is evidence that patients taking venlafaxine discontinue the drug due to its side effects. In addition, whereas venlafaxine has proven to have an efficacy equal to TCA, there are not yet systematic studies comparing the efficacy of duloxetine and TCAs (51, 54). A meta-analysis comparing 105 studies on the difference in efficacy among antidepressants reported that no specific difference exists among the agents.
Key question 6-5. When compared to other antidepressants, do NaSSAs (mirtazapine) have a different antidepressive efficacy?
Evidence
The NICE, CANMAT, APA, BAP, ACP, WFSBP, Clinical Research Center for Depression, and the Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have described mirtazapine as having equal treatment efficacy to other antidepressants (3, 12, 13, 16, 17, 21, 25, 27). The NICE guideline described the possibility of reaching remission and decreasing depressive symptoms was greater compared to SSRIs, but no clinical significance was observed (12). However, mirtazapine was described to be less prone to early discontinuation compared to other antidepressants. The APA and Clinical Research Center for Depression guidelines described mirtazapine as having earlier onset of treatment efficacy compared to fluoxetine, paroxetine, and sertraline (3, 16, 36, 55, 56), but no significant difference was observed in the response rate. The APA guideline described mirtazapine as having equal efficacy to SSRIs (16, 57).
Key question 6-6. When compared to other antidepressants, do NDRIs (bupropion) have a different antidepressive efficacy?
Key question 6-7. When compared to other antidepressants, do SARIs (trazodone) have a different antidepressive efficacy?
Evidence
The APA and Clinical Research Center for Depression guidelines reported trazodone to have an efficacy equal to that of TCAs and other antidepressants (3, 16). However, the CANMAT guideline described trazodone as not having a superior antidepressive efficacy compared to mirtazapine (17, 59), and the APA guideline described trazodone as showing inferior efficacy when treating severe depression or depression with severe psychomotor retardation compared to other antidepressants (16, 60, 61).
Key question 7. When is the appropriate time to assess treatment efficacy if symptoms do not improve with antidepressant treatment?
Evidence
The NICE, CANMAT, and WFSBP guidelines have recommended 2-4 weeks as the appropriate time for assessment, and the BAP, Hong Kong, and Clinical Research Center for Depression guidelines have recommended at least 4 weeks before assessment (3, 12, 13, 17, 21, 24). The New Zealand guidelines group and TDMHMR in collaboration with Texas universities guidelines recommended 4-6 weeks (14, 26), the APA guideline recommended 4-8 weeks, and the ACP guideline recommended 6-8 weeks (16, 25).
Key question 8. When there is an insufficient treatment response to first-line treatment, how should treatment be complemented?
Evidence
The New Zealand guidelines group, NICE, APA, BAP, WFSBP, Clinical Research Center for Depression, and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have recommended switching medication (3, 12, 13, 14, 16, 21, 27). The CANMAT, APA, BAP, Japan, TDMHMR in collaboration with Texas universities, WFSBP, Clinical Research Center for Depression, and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have recommended drug augmentation (3, 13, 16, 17, 21, 26, 27). The NICE, CANMAT, APA, BAP, TDMHMR in collaboration with Texas universities, WFSBP, Clinical Research Center for Depression, and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have recommended combination treatment with another antidepressant (3, 12, 13, 16, 17, 21, 26, 27). The New Zealand guidelines group, NICE, BAP, JCP, and Clinical Research Center for Depression guidelines have recommended an increase in dosage (3, 12, 13, 14).
Key question 9. When first-line treatment does not result in treatment response, does increasing the dosage help achieve treatment response?
Key question 9-1. When treatment with TCAs does not result in treatment response, does increasing the dosage help achieve treatment response?
Evidence
The BAP and Clinical Research Center for Depression guidelines have indicated that increasing the dosage of TCAs is effective (3, 13). The BAP guideline reported that TCAs in high dosages (equivalent to 200-300 mg of imipramine) was more effective than standard dosages (13), and the Clinical Research Center for Depression guideline reported that TCAs showed better efficiency at higher blood levels, through studies reporting the correlation of clinical efficiency and drug blood level measured by therapeutic drug monitoring (3).
Key question 9-2. When treatment with MAOIs does not result in treatment response, does increasing the dosage help achieve treatment response?
Evidence
The Clinical Research Center for Depression guideline noted that increasing the dosage may be considered, but not enough evidence exists (3). Tranylcypromine, an irreversible MAOI, showed improved efficacy when increasing the dosage in the moderate- to high-dose range (90-180 mg/d), but increased efficacy was not observed in the moderate- to high-dose range according to some open label studies (62). Phenelzine was reported to show an increased treatment response with an increase in dosage in the moderate- to high-dose range (63).
Key question 9-3. When treatment with SSRIs (including escitalopram) does not result in a treatment response, does increasing the dosage help achieve treatment response?
Evidence
The APA guideline reported that a higher dosage of SSRIs is more effective (16). MDD patients were assigned randomly to 0, 10, 20, 40, or 60 mg/day, and it was reported that the groups taking 10-20 mg showed more improvement than the placebo-treated group, but less improvement than the group taking 40-60 mg (64). However, the groups taking 20, 30, and 40 mg showed more side effects than the placebo group. The BAP guideline reported 20 mg of escitalopram as having better efficacy than 10 mg (13). On the other hand, the Clinical Research Center for Depression guideline indicated that increasing the dosage of fluoxetine and sertraline in treatment-resistant MDD patients did not significantly improve symptoms compared to maintaining the same dosage in such patients (3, 65, 66). Furthermore, a previous study reported that an increase in the dosage of paroxetine did not significantly improve symptoms (67).
Key question 9-4. When treatment with SNRIs (milnacipran, venlafaxine and duloxetine) does not result in treatment response, does increasing the dosage help achieve treatment response?
Evidence
The BAP guideline suggested that in treatment non-resistant patients, 225-375 mg of venlafaxine is more effective than 75 mg (68). The Clinical Research Center for Depression guideline also stated that at the highest doses, venlafaxine showed superior efficacy (3, 68, 69), and recommended that when patients do not show sufficient efficacy in the low dose range, dosages should be increased. However, studies comparing duloxetine in dosages of 40 mg and 80 mg, 30 mg and 60 mg, and 80 mg and 120 mg reported that the efficacy and receptivity did not have a statistically and clinically significant difference between the groups, although not many studies have been performed. Therefore, it was recommended that a dosage over 60 mg is not more effective.
Key question 10. When first-line antidepressant treatment does not result in treatment response, does switching to another agent help achieve treatment response?
Key question 10-1. When there is no response to SSRIs, does switching to another agent help treatment?
Evidence
The CANMAT, BAP, WFSBP, and Clinical Research Center for Depression guidelines referenced 3 studies including a STAR*D study, reporting that when SSRIs are not effective, switching to venlafaxine showed a 54% remission rate (3, 13, 17, 21, 70, 71). Further, the Clinical Research Center for Depression guideline referenced studies reporting it is effective to switch to TCAs when SSRIs are not effective. Also the medications preferred by psychiatrists in Korea were reported to be venlafaxine, mirtazapine, milnacipran, and bupropion (3). The CANMANT guideline also referenced a meta-analysis of 8 randomized controlled trials that reported when switching from SSRIs to other antidepressants, significant differences in treatment efficacy were not shown between antidepressants (17).
Key question 11-1. Is the combination treatment of TCAs and another antidepressant efficacious?
Evidence
The BAP guideline reported that the combination treatment of amitriptyline and moclobemide was more efficacious than amitriptyline therapy alone (13). The APA guideline reported that the combination treatment of TCAs and SSRIs shows a higher remission rate compared to therapy with either TCAs or SSRIs (16, 72).
Key question 11-2. Is the combination treatment of MAOIs and another antidepressant efficacious?
Evidence
The NICE and BAP guidelines reported that randomized control trials on the combination treatment of MAOIs and another antidepressant have been insufficient (12, 13). In particular, the number of controlled trials on the benefits or potential interactions of the combination treatment of TCAs and MAOIs in treatment-resistant depression is insufficient (73).
Key question 11-3. Is the combination treatment of SSRIs and another antidepressant efficacious?
Evidence
The APA, BAP, NSCCMHDA and University of Sydney CADE Clinic, Clinical Research Center for Depression, and Hong Kong guidelines have recommended the combination treatment of SSRIs and another antidepressant (3, 13, 15, 16, 24). The efficacy of the combination treatment of mirtazapine and SSRIs was proven in a placebo-controlled study (74). The BAP guideline reported that the combination of reboxetine, bupropion, and TCAs with SSRIs are the most widely used (13). The Clinical Research Center for Depression guideline described combination treatments of SSRIs and bupropion, while SSRIs and mirtazapine are the most preferred by psychiatrists in Korea (3). However, the combination of SSRIs and TCAs is still controversial. SSRIs hinder the metabolism of certain TCAs, and as a result, the blood pressure can rise, and toxicity and side effects can increase. In addition, the Clinical Research Center for Depression guideline noted that SSRIs and other antidepressants are used widely in combination in clinical settings, but most studies that are the basis of such use are open studies or case reports (3).
Key question 11-4. Is the combination treatment of SNRIs and another antidepressant efficacious?
Evidence
The APA guideline reported that the combination treatment of venlafaxine and mirtazapine will achieve a remission rate of 13.7% in patients that did not previously respond to 3 different medications (16, 75). On the other hand, the Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guideline reported that there is not much evidence on the effectiveness of the combination of venlafaxine and SSRIs (27). Further, when SSRIs that can suppress the metabolism of venlafaxine by CYP2D6 are taken in combination with venlafaxine, the blood level of venlafaxine can increase, and as a result, increased blood pressure, serotonin syndrome, and severe anticholinergic side effects may occur; hence, the combination of the agents must be performed with caution.
Key question 11-5. Is the combination treatment of NASSAs (mirtazapine) and another antidepressant efficacious?
Evidence
The CANMAT, BAP, and Clinical Research Center for Depression guidelines described the combination treatment of mirtazapine or mianserin and other antidepressants (bupropion, venlafaxine, SSRIs, TCAs) as helpful (3, 13, 17). The CANMAT and APA guidelines have noted that the combination treatment of mirtazapine and SSRIs was shown to be superior in a placebo-controlled study (16, 17, 74).
Key question 11-6. Is the combination treatment of NDRIs (bupropion) and another antidepressant efficacious?
Evidence
The CANMAT, APA, BAP, WFSBP, and the Clinical Research Center for Depression guidelines all reported that the combination treatment of bupropion and SSRIs is efficacious (3, 13, 16, 17, 21). When unresponsive to citalopram, bupropion was shown to be superior to buspirone in effectiveness and tolerability when used in combination with citalopram (21). The combination treatment of SSRIs and bupropion was also shown to have superior efficacy to either agent used as monotherapy (76). The CANMAT guideline noted that many open-label studies and cohort studies have reported bupropion to be efficacious, but randomized controlled trials have not reported such efficacy (17, 77).
Key question 11-7. Is the combination treatment of SARIs (trazodone) and another antidepressant efficacious?
Key question 12-1. Is adding lithium to an antidepressant helpful in the treatment of depression?
Key question 12-2. Is adding an anticonvulsant to an antidepressant helpful in the treatment of depression?
Evidence
The NICE, APA, BAP, Clinical Research Center for Depression, and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have suggested that evidence on the efficacy of anticonvulsant augmentation therapy is insufficient (3, 12, 13, 16). However, in those who did not respond to treatment previously, when a lamotrigine and fluoxetine augmentation group was compared to a lamotrigine monotherapy group, lamotrigine showed partial efficacy (82). Further, lithium and lamotrigine showed no significant difference in efficacy (53% vs 41%) (83).
Key question 12-3. Is adding T3 to an antidepressant helpful in the treatment of depression?
Evidence
The NICE, CANMAT, APA, BAP, WFSBP, TDMHMR in collaboration with Texas universities, Clinical Research Center for Depression, and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have described T3 augmentation to be clinically efficacious in the treatment of depression (3, 12, 13, 15, 16, 17, 21, 26, 27).
Key question 12-4. Is adding a benzodiazepine to an antidepressant helpful in the treatment of depression?
Evidence
The CANMAT, BAP, Hong Kong, NSCCMHDA and University of Sydney CADE Clinic, and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have recommended the short-term use of benzodiazepines (13, 15, 17, 24). However, the NICE guideline described benzodiazepines to have insufficient evidence compared to placebo (12). The APA guideline reported that the use of antianxiety drugs and sedatives with SNRIs and SSRIs is not recommended for persistent anxiety and insomnia (16). The BAP and Hong Kong guidelines also recommended to be cautious about the risks of long-term use (13, 24).
Key question 12-5. Is adding atomoxetine to an antidepressant helpful in the treatment of depression?
Key question 12-6-1. Is adding methylphenidate to an antidepressant helpful in the treatment of depression?
Key question 12-6-2. Is adding modafinil to an antidepressant helpful in the treatment of depression?
Evidence
The CANMAT, BAP, APA, and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have described modafinil as having a low possibility of causing dependency and cardiovascular side effects (13, 16, 17, 27). In addition, modafinil is described as being helpful with residual symptoms such as fatigue and sedation (84, 85). However, the CANMAT guideline has described two meta-analyses of placebo-controlled RCTs that have reported that, despite many advantages, overall negative results (17, 84, 85).
Key question 13-1. How long should antidepressant treatment be continued in continuation therapy?
Evidence
The New Zealand guidelines group, NICE, APA, TDMHMR in collaboration with Texas universities, and WFSBP guidelines have recommended that adult patients who have responded to antidepressant treatment should continue more than 6 months of antidepressant therapy in order to prevent relapse (12, 14, 16, 21, 26). The APA guideline recommended that patients who were successfully treated in the acute phase should continue treatment for 4-9 months (16). The TDMHMR in collaboration with Texas universities guideline recommended continuing therapy for 6-9 months after remission (26). The WFSBP guideline recommended continuing therapy for more than 9 months, considering the patient's psychiatric history, and if there are persisting symptoms, treatment should be continued until all symptoms resolve (21).
Key question 13-2. How long should antidepressant treatment be continued in maintenance therapy?
Evidence
The Hong Kong, NSCCMHDA and University of Sydney CADE Clinic, WFSBP, and Clinical Research Center for Depression guidelines have recommended that patients with recurrent MDD continue treatment for 3 yr (3, 15, 21, 24). The APA guideline has recommended maintenance therapy for patients who have experienced 3 or more depressive episodes (16), while the Hong Kong and NSCCMHDA and University of Sydney CADE Clinic guidelines have recommended maintenance therapy of 3-6 months or 1 yr after the first depressive episode (15, 24).
Key question 14. What are the withdrawal symptoms of antidepressants and the management of such symptoms?
Evidence
The NICE, APA, ACP, and NSCCMHDA and University of Sydney CADE Clinic guidelines have described the withdrawal symptoms of antidepressants to include an increase in mood fluctuation (for example, hypersensitivity), gastrointestinal symptoms (nausea), neuromotor abnormalities (ataxia), vasomotor abnormalities (sweating), neurosensory abnormalities (sensory abnormalities), insomnia and other neurological problems (12, 15, 16, 25). The NSCCMHDA and University of Sydney CADE Clinic guideline described general withdrawal symptoms of SSRIs as flu-like symptoms, a shock-like sensation, dizziness, dreaming excessively, insomnia, and tearing. The general withdrawal symptoms of TCAs were described as flu-like symptoms and insomnia (15). The APA and ACP guidelines reported that paroxetine may have a long-term discontinuation syndrome, and venlafaxine may have similar symptoms as well (16, 25). Most of the guidelines have recommended a slow tapering down of antidepressants or retaking the previous antidepressant or switching to an antidepressant that has a long half-life.
Recommendations
It is strongly recommended that antidepressants be tapered slowly as to prevent withdrawal symptoms. When withdrawal symptoms appear, it is strongly recommended that the previous medication be taken again or that an antidepressant in the same line with a longer half-life be administered.
Key question 15. Do antidepressants influence the suicide of MDD patients?
Evidence
The CANMAT, APA, BAP, Hong Kong, and WFSBP guidelines have reported that there is no clear evidence on whether antidepressants increase suicide-related behaviors in adults (13, 16, 17, 21, 24). However, suicidal risks may increase in patients under 30 yr old who are receiving initial treatment, and the APA guideline has quoted the results of a meta-analysis reporting that suicidal ideation and rates were statistically 1.5-2.5 times higher in patients 25 yr old and under, compared to control groups (16). On the other hand, the ACP guideline quoted a meta-analysis reporting no evidence that antidepressants increase suicide risks, but the risk of suicide attempts that are not fatal may increase (25, 86).
Key question 16-1. Are there differences in sexual side effects among different antidepressant treatments?
Evidence
The NICE, CANMAT, APA, BAP, ACP, TDMHMR in collaboration with Texas universities, Clinical Research Center for Depression, and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have reported that SSRIs have higher sexual side effects, and among the SSRIs, paroxetine has a higher rate of sexual dysfunction compared to other antidepressants (3, 12, 13, 16, 17, 25, 26, 27). The CANMAT, ACP, TDMHMR in collaboration with Texas universities, Clinical Research Center for Depression, and Korean Society for Depressive and Bipolar Disorders and Korean College of Neuropsychopharmacology guidelines have described bupropion as having a similar rate of sexual side effects to placebo (3, 17, 25, 26, 27). It was also recommended to switch to bupropion when sexual side effects arise from other antidepressants (87). Furthermore, mirtazapine was reported to cause sexual side effects at a similarly low rate to bupropion. The ACP guideline described paroxetine as causing sexual side effects; however, the exact rate has not yet been reported (25).
DISCUSSION
A clinical practice guideline can be defined as a systematic description that helps clinicians and patients choose their health management program in a specific clinical situation. The present guideline was developed to reduce the discrepancies in clinical treatment, inappropriate levels of treatment, and treatment costs by improving the quality of treatment in Korea. Not only the USA and UK, but also Canada, New Zealand, and Singapore are developing their own evidence-based guidelines. Guidelines that have been developed by evidence-based methods are becoming the mainstream treatment modality worldwide for the following reasons: First, given the huge amount of published research these days, no one individual can keep up with the rate of development of medical knowledge; second, treatment recommendations may be contradictory among experts, and if clinical practice is only based on the judgment of the practitioner, different recommendations may be made in the same clinical situation.
In summary, our evidence-based treatment guideline has made certain recommendations considered appropriate to the current clinical situation of Korea (Table 2). The revised edition of the treatment guideline is considered to comprise new clinical information, and to reflect the current clinical situation of Korea, when compared to the previous version. Furthermore, the Evidence-based, Non-pharmacological Treatment Guideline for Depression in Korea (4) has also been developed, which strengthens the holistic approach of the guidelines to the treatment of depression when used together. The next step for the treatment guideline development team to take may be harmonizing the pharmacological and non-pharmacological treatment guidelines to a single comprehensive guideline, in order to complete the holistic approach to treating depression. Until further development of specific methodologies for the pharmacological treatment of depression is achieved in Korea, we recommend the wide distribution of the Evidence-based Pharmacological Treatment Guideline for Depression in Korea, Revised Edition, so that it is available to all clinical practitioners. The guideline is considered to be helpful when selecting the appropriate pharmacological treatment for MDD patients in Korea.
XML Download